作者: Francesco Sartini , Michele Figus , Marco Nardi , Giamberto Casini , Chiara Posarelli
DOI: 10.1038/S41433-019-0381-7
关键词:
摘要: Central serous chorioretinopathy is one of the most frequent causes vision reduction among middle-aged men. This disease usually has a self-limiting course, but sometimes it lasts more than 4–6 months or second episode follows complete resolution first one. Nevertheless, to date no consensus exists about duration threshold and therapy protocols for these non-resolving central chorioretinopathy. Treatment as half-dose half-fluence photodynamic therapy, subthreshold micropulse laser treatment, mineralocorticoid receptor antagonists, intravitreal anti-angiogenic drugs, transpupillary thermal anti-androgenic methotrexate, Rifampicin melatonin are described in this review. Complications very uncommon end-point results like macular thickness best-corrected visual acuity improvement difficult compare different therapeutic modalities due follow-up lack homogeneity patient recruitment. The aim review focusing on treatment chronic forms with comprehensive recent management updates according latest clinical trial results.